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The role of resistin as a regulator of inflammation: Implications
for various human pathologies
Abstract
Resistin was originally described as an adipocyte-secreted peptide that induced insulin resistance in
rodents. Increasing evidence indicates its important regulatory roles in various biological processes,
including several inflammatory diseases. Further studies have shown that resistin in humans, in contrast
to its production by adipocytes in mice, is synthesized predominantly by mononuclear cells both within
and outside adipose tissue. Possible roles for resistin in obesity-related subclinical inflammation,
atherosclerosis and cardiovascular disease, non-alcoholic fatty liver disease, rheumatic diseases,
malignant tumors, asthma, inflammatory bowel disease, and chronic kidney disease have already been
demonstrated. In addition, resistin can modulate several molecular pathways involved in metabolic,
inflammatory, and autoimmune diseases. In this review, current knowledge about the functions and
pathophysiological implications of resistin in different human pathologies is summarized, although there
is a significant lack of firm evidence regarding the specific role resistin plays in the "orchestra" of the
numerous mediators of inflammation.
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Abstract  
Resistin was originally described as an adipocyte-secreted peptide that induced insulin 
resistance in rodents. Increasing evidence indicates its important regulatory roles in various 
biological processes, including several inflammatory diseases. Further studies have shown 
that resistin in humans, in contrast to its production by adipocytes in mice, is synthesized 
predominantly by mononuclear cells both within and outside adipose tissue. Possible roles for 
resistin in obesity-related subclinical inflammation, atherosclerosis and cardiovascular 
disease, non-alcoholic fatty liver disease, rheumatic diseases, malignant tumors, asthma, 
inflammatory bowel disease, and chronic kidney disease have already been demonstrated. In 
addition, resistin can modulate several molecular pathways involved in metabolic, 
inflammatory, and autoimmune diseases. In this review, current knowledge about the 
functions and pathophysiological implications of resistin in different human pathologies is 
summarized, although there is a significant lack of firm evidence regarding the specific role 
resistin plays in the “orchestra” of the numerous mediators of inflammation. 
 
 
 
Key words: resistin, inflammation, obesity, cancer, molecular pathway  
 3 
List of Contents 
1. Introduction        4 
2. Structure of resistin       4 
3. Sites of resistin production      6 
4. The role of resistin in inflammation and signaling pathways  6 
5. Resistin, obesity, and markers of insulin resistance   8 
6. Resistin and atherosclerosis      11 
7. Resistin and non-alcoholic fatty liver disease   13 
8. Involvement of resistin in malignancies    14 
9. Resistin in rheumatic diseases      14 
10. Resistin and bone metabolism     16 
11. Resistin and inflammatory bowel diseases    16 
12. Resistin and chronic kidney disease     17 
13. Resistin and asthma       18 
14. Resistin as a potential pharmacological target   18 
15. Conclusion        20 
Acknowledgement 
References 
 
 
Formatiert: Schriftart: Times
New Roman, 12 pt, Fett,
Schriftartfarbe: Automatisch
Formatiert: Schriftart: Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Schriftart: Nicht
Fett
Formatiert: Standard, Links
 4 
Introduction 
White adipose tissue is an active organ that secretes a large variety of proteins known as 
adipokines. Adipokines include several cytokines, chemokines, and hormone-like factors that 
participate in the regulation of physiological and pathological processes such as metabolism, 
immunity, and inflammation [1, 2]. Resistin, known as adipocyte-secreted factor (ADSF) or 
found in inflammatory zone 3 (FIZZ3), was discovered in 2001 and was proposed as a 
potential link between obesity and diabetes [3]. The administration of recombinant resistin to 
diet-induced and genetically obese mice impaired glucose tolerance. Blocking resistin action 
improved blood sugar in obese mice but impaired glucose tolerance in healthy ones. 
Moreover, resistin decreased glucose uptake in skeletal muscle cells, although this effect was 
independent of insulin signaling pathways [4]. An acute increase in serum resistin in rats has 
also been shown to result in severe hepatic insulin resistance [5]. 
The aim of this review was to update the reader on recent findings regarding the roles of 
resistin in obesity-related, inflammatory, and autoimmune diseases, as well as in cancer.  
 
Structure of resistin 
A family of resistin-like molecules (RELMs) has recently been identified. These polypeptides 
of 105-114 amino acids have three domains: an N-terminal signal sequence, a variable middle 
portion, and a highly constant C-terminal sequence that determines the signature of the 
molecule [6, 7]. RELM-α (FIZZ 1) is a secreted protein that is present mainly in adipose 
tissue and found in the inflammatory zone in murine allergic pulmonary inflammation [8]. 
RELM-β (FIZZ 2) is secreted only in the gastrointestinal tract from goblet and epithelial cells, 
and it is markedly expressed in tumors, suggesting a possible role in proliferation [7]. RELM-
γ, the most recently discovered member of the RELM family, is found in hematopoietic 
tissue, indicating cytokine-like functions [9]. 
 5 
Resistin is a 12.5 kDa cysteine-rich protein that consists of 108 amino acids in humans and 
114 amino acids in mice, including a 17-amino acid signal peptide, a variable region of 37 
amino acids, and a conserved C terminus [7, 10, 11]. The mouse resistin gene is located on 
chromosome 8, and the human resistin gene is on chromosome 19. The mouse and human 
resistins share 46.7% similarity at the genomic DNA level, 64.4% sequence homology at the 
mRNA level, and 59% identity at the amino acid level [10]. Its protomer contains a disulfide-
rich beta-sandwich “head” domain at the C terminus that is linked to a helical “tail” region at 
the N terminus. The head contains two three-stranded all-antiparallel sheets. The globular 
domain of resistin contains five disulfide bonds that are topologically conserved in the RELM 
structure. Three protomers associate through the formation of a parallel coiled coil. These 
trimers are further interlinked to form tail-tail hexamers, linking each protomer from one 
trimer to a protomer from the associated trimer and forming a short antiparallel six-helix 
bundle. The nature of this interface suggests that the hexamer association would be unstable.  
Mouse resistin exists predominantly as an α-helical form [12]. In the mouse, resistin circulates 
in two forms: a high-molecular weight (HMW) form that is identical to the disulfide-linked 
hexamer and a low-molecular weight (LMW) form that represents a smaller trimer complex 
that is unable to form intertrimer disulfide bonds [13]. The LMW monomeric form in mice is 
considered to be more bioactive and potent in terms of hepatic insulin action impairment. 
Indeed, resistin may have to be processed to the LMW form before it can exert its activity. In 
contrast to the liver, the biological action of resistin in the cardiac muscle of mice requires 
oligomerization [14].  
Human resistin shows a concentration-dependent reversible conformational shift to the β-
sheet form that may regulate its function and distinct physiological properties [15]. It 
circulates as an oligomer with a molecular mass >660 kDa and a trimer of 45 kDa [16]. 
Human resistin has a tendency to form oligomers that are, in contrast to mice, biologically 
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more active [15, 16, 17]. However, both the oligomeric and dimeric forms of resistin are able 
to activate tumor necrosis factor (TNF)-α and interleukin (IL)-12 in macrophages and 
monocytes [18]. The main differences between the mouse and human resistins are highlighted 
in Table 1. It is possible that the structural conformation of resistin may be involved in 
maintaining the very fine balance of various pathological conditions [15].  
 
Sites of resistin production 
Although murine and human resistin share more than 50% identity at the amino acid level, 
their expression patterns are different [19]. In mice, resistin is almost exclusively expressed in 
white adipose tissue in proportion to adipocyte differentiation and the amount of adipose 
tissue [3]. It has also been found in the pituitary gland, the hypothalamus, and in the blood 
circulation [20]. Resistin in rats is secreted not only by adipose tissue, but has also been found 
in the gastrointestinal tract, adrenal glands, skeletal muscles, pancreas, and spleen [21, 22, 
23]. In contrast to mice, only a low level of expression of resistin has been found in mature 
adipocytes in humans [24-27]. In humans, resistin is highly expressed in the bone marrow 
compared to other tissues [28], but it is also present in trophoblastic cells of placenta, 
pancreas, primary cell leukemia, synovial fluid, synovial tissue, and circulating blood [22, 24, 
28-34]. The particular cells that express resistin in white adipose tissue are monocytes and 
macrophages [26, 28, 35]. Based on these data, the presence of resistin in human adipose 
tissue is mostly due to its production by the non-fat stroma-vascular fraction of adipose tissue.  
 
The role of resistin in inflammation and signaling pathways  
Although resistin was first postulated to contribute to insulin resistance, it has recently been 
shown that  resistin can trigger a proinflammatory state “in vitro” as well as “in vivo” [36]. 
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Despite the numerous recent studies concerning resistin pathophysiology, little is known 
about how resistin acts in the process of inflammation.  
The expression of resistin is up-regulated during monocyte-macrophage differentiation, 
indicating a role for resistin in monocyte-macrophage function [26, 28]. It has been 
demonstrated that proinflammatory mediators such as TNF-α, IL-1β, IL-6, or 
lipopolysaccharide (LPS) can strongly increase the expression of resistin in peripheral blood 
mononuclear cells (PBMCs), suggesting a role for resistin in the process of inflammation [36-
39]. In addition, C-reactive protein (CRP) induced both mRNA expression and protein 
secretion of resistin in a dose- and time-dependent manner in PBMCs [40]. 
Silswal et al. incubated both human and mouse macrophages with human recombinant resistin 
and found increased production of the proinflammatory cytokines TNF-α and IL-12. As the 
authors showed, this induction was mediated through the transcription factor NF-κB [17]. 
Resistin induced dose-dependent NF-κB activity in PBMCs, which resulted in the 
translocation of both the p65 and p50 subunits of NF-κB from the cytoplasm to the nucleus 
[36]. This effect may occur through resistin-mediated phosphorylation of the inhibitory 
protein IκBα and the p65 subunit of NF-κB [40]. Resistin increased the cytosolic calcium 
concentration via an influx of calcium from the extracellular environment and activation of 
phospholipase C (PLC), leading to the release of calcium from intracellular pools [41].  
Resistin is minimally expressed in human primary adipocytes, but these may be target cells 
for resistin. Nagaev and coworkers demonstrated that, similar to its actions in PBMCs, resistin 
could induce the expression of the proinflammatory cytokines IL-6, IL-8, and TNF-α by white 
adipose tissue in vitro [42]. Resistin targets human adipocytes and, similar to TNF-α, 
enhances inflammatory processes in adipose tissues. In contrast to TNF-α, resistin does not 
induce the suppression of adipose-specific markers (CEBPA, FABP4, and SLC2A4). This 
suggests that resistin's intracellular signaling pathway is distinct from that of TNF-α, even 
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though both activate NF-κB. Recombinant human resistin is also capable of increasing the 
production of the proinflammatory cytokines IL-8 and monocyte chemoattractant protein 
(MCP)-1 via the activation of NF-κB [42]. Both mitogen-activated protein kinases (MAPKs), 
such as Erk or p38, and Akt, as a downstream substrate of phosphatidylinositol 3-kinase 
(PI3K), can be phosphorylated by resistin in several cell lines [41, 43-45]. The intracellular 
signaling pathways of resistin are shown in Figure 1. In a human study, experimental 
endotoxemia caused a hyperresistinemic state [42]. In light of this, cytokines have been 
proposed to increase the levels of resistin, which may contribute to insulin resistance in 
obesity and several other inflammatory disorders [38, 46-54]. Potential roles for resistin in 
obesity, inflammatory, and other related diseases are shown in Figure 2. 
 
Resistin, at least in humans, shares several features with proinflammatory cytokines and can 
play a role in the regulation of inflammation and immunity [52].  
  
Resistin, obesity, and markers of insulin resistance 
Resistin has been shown to be increased in the mouse models of genetic and diet-induced 
obesity. The administration of resistin to healthy mice impaired glucose tolerance as well as 
insulin action, and antibody against resistin improved blood sugar and insulin action [3]. The 
mechanism of how resistin modulates glucose homeostasis is of great interest. Type 2 
diabetes mellitus is characterized by a progressive loss of beta-cell function. Resistin has 
recently been shown to induce beta-cell apoptosis in rat insulinoma. Beta-cell apoptosis 
induced by adipokines may thus result in beta-cell dysfunction in type 2 diabetes [55]. 
In 3T3-L1 adipocytes, resistin influences neither insulin binding nor the absolute levels of 
insulin receptor. However, it attenuates the insulin-signaling pathway upon decreased insulin-
dependent phosphorylation of the insulin receptor and subsequent reduction of downstream 
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signals [56]. Suppressor of cytokine signaling (SOCS) proteins are well known inhibitors of 
insulin signaling. In adipocytes, resistin activates SOCS3 in a time- and dose-dependent 
manner and induces the association of SOCS3 with the insulin receptor. It is possible that 
SOCS3 could be a cellular mediator of the ability of resistin to antagonize insulin action in 
adipocytes [56].  
In rat skeletal muscles, resistin inhibits insulin-stimulated glycogen synthesis and glucose 
uptake [4, 57]. Resistin alters neither the insulin receptor content nor its phosphorylation. 
Decreased glucose uptake is also independent of GLUT4 translocation from intracellular 
pools to the cell membrane. The inhibitory effect of resistin on glycogen synthesis may be due 
to a reduction in the intrinsic activity of glucose transporters [57].  
Resistin also exerts its glucoregulatory effect by stimulating hepatic glucose output [5, 58, 59, 
60]. Resistin decreased insulin receptor and glycogen synthase activity and increased the 
activity of glycogen phosphorylase at the protein level but not the mRNA level [60]. This 
results in lower glycogen content in the liver due to attenuated glycogenesis and enhanced 
glycogenolysis [60]. Recently, a hypothalamus-mediated effect of resistin on hepatic glucose 
homeostasis was demonstrated. The central administration of recombinant resistin impaired 
the inhibitory action of insulin on hepatic glycogenolysis but did not alter the hepatic 
expression of the key gluconeogenic enzymes [61]. 
Transcription factors implicated in adipogenesis include C/EBP family members and the 
peroxisome proliferator activated receptor γ (PPARγ), which is the main regulator. Resistin 
expression was enhanced by the overexpression of C/EBPα and reduced by the 
overexpression of PPARγ [62]. It has been shown that the mouse resistin promoter contains a 
C/EBPα binding site, and this binding is accompanied by a higher acetylation of histones at 
the resistin promoter. Moreover, PPARγ ligands reduced histone acetylation without inducing 
a change in C/EBPα recruitment [63].  
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Thus, resistin exerts its potent metabolic actions on the liver, skeletal muscles, and adipocytes 
through peripheral and central mechanisms. Considering this and the effect of PPARγ 
activation, resistin could become a target for anti-diabetic agents. 
An obesity-related inflammatory state is linked to the increased risk of developing 
cardiovascular diseases and type 2 diabetes mellitus [64]. Immune cells infiltrating fat create a 
milieu that perpetuates inflammation within the adipose tissue and stimulates the adipocytes 
themselves to produce inflammatory mediators, including adipokines, completing a vicious 
circle of inflammation related to obesity [65-68].  
Large fat cells and increased ectopic deposition of fat with increased intramyocellular lipids 
are postulated to be predictors of the development of type 2 diabetes [,69, 70]. However, it 
has been shown that neither fat cell size nor percent body fat is related to serum resistin [71]. 
There is either no difference in serum resistin levels among non-obese, obese and obese 
diabetic groups, despite wide variations in insulin sensitivity, or resistin is increased in obese 
subjects. Similarly, resistin is not a significant predictor of insulin resistance when adjusted 
for adiposity [71, 72]. These results suggest that resistin is neither related to adiposity nor 
associated with increased intramyocellular or intrahepatic lipid contents. In agreement with 
this, other studies have revealed no correlations between adiposity, body weight, and other 
metabolic parameters, including insulin sensitivity and resistin mRNA expression in isolated 
adipocytes [26, 27]. Resistin expression in adipose tissue from morbidly obese patients is 
significantly higher compared to lean subjects but does not correlate with the body mass index 
(BMI) [26]. A possible explanation for this could be a higher proportion of mononuclear cells 
expressing resistin mRNA in the adipose tissue of obese individuals. In one longitudinal 
study, it was observed that the percent change in serum resistin level positively correlated 
with the percent change in fat mass rather than the percent change in BMI [73]. 
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In spite of great interest in how resistin impairs insulin sensitivity, there is continued 
uncertainty about the possible relationship between resistin and markers of insulin resistance 
[74]. However, the higher production of resistin by the non-fat components of adipose tissue 
might explain the abovementioned controversial findings in obese patients [35]. Moreover, 
resistin can amplify inflammatory responses in the liver via the central nervous system, which 
may represent a novel mechanism leading to the decrease of insulin sensitivity and related 
development of atherosclerosis and hyperlipidemia that are associated with metabolic 
syndrome [61].  
 
Resistin and atherosclerosis 
The cardiovascular complications of obesity have been specifically explained by endothelial 
and vascular dysfunction [75]. Obesity, type 2 diabetes, and cardiovascular disease have been 
increasingly recognized as inflammatory conditions due to an increased presence of 
proinflammatory mediators [51, 76]. The research on adipokines in the last 20 years has 
finally provided a plausible link between obesity and cardiovascular diseases [77].  
Plasma resistin levels have been associated with markers of inflammation such as TNF-α, 
soluble TNF-α receptor-2, or IL-6 and moreover, resistin has been shown to be a predictive 
factor for coronary atherosclerosis in humans, independent of CRP [54, 78, 79]. It was 
recently shown that resistin correlates with the levels of biomarkers for cardiac injury, and it 
has been suggested as a marker of the severity of myocardium ischemic injury [80].  
In rodents, resistin is derived largely from adipose tissue, and hyperresistinemia impairs 
glucose tolerance in mice. In contrast to animal models, immunocompetent cells appear to be 
the major source of resistin in humans, rather than adipocytes [28]. Resistin was found both 
intracellularly in macrophages as well as extracellularly in atheromas [81]. It contributes to 
glucose-dependent increases in triglyceride and cholesterol cellular mass that do not occur in 
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the absence of resistin [82]. Resistin also promotes foam cell formation via the up-regulation 
of SR-A and CD36 scavenger receptors and downregulation of the reverse cholesterol 
transporter ABCA1 (ATP-binding cassette transporter A1) [83].  
Resistin was recently suggested as a mediator of endothelial dysfunction, and it has been 
shown to promote the activation of endothelial cells via the release of endothelin (ET-1). 
Furthermore, it induces the expression of vascular cell adhesion molecule (VCAM-1), inter-
cellular adhesion molecule 1 (ICAM-1), vascular endothelial growth factor receptors 
(VEGFR), matrix metalloproteinases (MMPs), and MCP-1; it also reduced TNF receptor-
associated factor 3 (TRAF3), a key inhibitor of CD40 signaling in endothelial cells [45, 84, 
85]. These “in vitro” data were confirmed by functional studies showing that resistin induces 
proliferation and migration of human endothelial cell and promotes capillary-like tube 
formation [45, 86, 87]. As it was recently reported, this could be mediated via resistin- 
activated TWEAK (TNF-like weak inducer of apoptosis), and it is independent of altered 
nitric oxide (NO) production [86, 88]. Resistin also promotes the smooth muscle cell 
proliferation that may account in part for the increased incidence of restenosis [43].  
Angiogenesis in an atherosclerotic plaque contributes to its vulnerability, which may lead to 
rupture and subsequent intra-arterial occlusion [89]. In contrast, revascularization and 
collateral circulation is a desired process in the ischemic heart muscle and limb and is 
becoming the therapeutic goal [90]. However, a principle reason for the failure of angiogenic 
therapy could be the decreased effectiveness of growth factors due to endothelial dysfunction 
[91]. Although resistin was reported to promote angiogenesis [45, 86], which would be 
beneficial for ischemic muscle, a resistin-mediated impairment of endothelium function could 
diminish its angiogenic effect. Moreover, resistin has been shown to impair glucose 
metabolism in mouse cardiomyocytes and to worsen cardiac ischemia-reperfusion injury in 
rats. This could be due to stimulated cardiac TNF-α secretion and the reperfusion release of 
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natriuretic peptides and biochemical markers of myocardial damage [14, 87]. Furthermore, 
the abnormal formation of blood vessels also plays a role in other pathologies such as tumors, 
diabetic retinopathy, rheumatoid arthritis, or systemic lupus erythematosus. Since resistin may 
be a part of their pathophysiology, blocking resistin might prevent the abundant angiogenesis 
that is a typical sign of the abovementioned diseases. 
 
Altogether, these data indicate that resistin may contribute to the accumulation of cholesterol 
and triglycerides in macrophages, arterial inflammation, endothelial dysfunction, and 
angiogenesis. These may contribute to accelerated atherogenesis and coronary heart disease. 
Moreover, resistin has been suggested as a marker of coronary atherosclerosis and the severity 
of myocardium ischemic injury. 
 
Resistin and non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic 
syndrome, which is mainly characterized by an excessive hepatic deposition of free fatty acids 
and triglycerides in the hepatic parenchyma. NAFLD ranges from steatosis to steatohepatitis, 
and potentially leads to fibrosis and end stage liver disease.  
A few studies have reported that serum resistin levels did not differ between patients with 
NAFLD and without the disease [92, 93]. However, one study has shown that excessive 
ectopic accumulation of fat in the liver and skeletal muscle of insulin-resistant subjects is 
associated with lower concentrations of resistin in the serum, while another reports increased 
levels of resistin, but only in patients with severe liver disease [94, 95].  
 
Thus, the results comparing serum resistin levels in patients with different stages of NAFLD 
have been controversial, and the contribution of resistin should be further explored.  
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Involvement of resistin in malignancies 
Obesity has been suggested as a risk factor for the development of some types of cancer. 
Several recent studies have indicated that some adipose tissue-derived peptides may 
significantly influence the growth and proliferation of tumorous stroma and malignant cells 
[96]. For example, elevated levels of plasma resistin have been found in females with breast 
cancer, and higher levels appear related to the highest histological grade, independent of age, 
body mass index, serum glucose, or menopause [97]. Furthermore, resistin levels are 
significantly higher in lymphoma patients than in patients with other hematological 
malignancies [98]. Another study has reported no differences in the staining pattern between 
benign and neoplastic prostate tissues [99].  
 
Although only a few studies have analyzed resistin in patients with malignancies, the general 
properties of resistin could contribute to tumorigenesis. For example, in choriocarcinoma, 
resistin induces the expression of MMPs, reduces the synthesis of tissue inhibitors of 
metalloproteinases (TIMP), and thereby increases the invasiveness of trophoblast-like cells 
[100]. Resistin has been also shown to induce production of VEGFR and the formation of 
endothelial cell tubes [45]. 
 
Resistin in rheumatic diseases  
Increased resistin levels have previously been observed in synovial fluid from patients with 
rheumatoid arthritis (RA) compared to patients with non-inflammatory rheumatic disorders 
[30]. These authors observed an association of synovial fluid resistin with inflammatory 
markers of the disease. Moreover, the association between serum resistin levels, disease 
activity, and acute phase reactants, including C-reactive protein and IL-1Ra antagonizing IL-
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1β, suggests that resistin may be a significant mediator in the inflammatory process of RA 
[31, 101]. On the contrary, serum resistin levels were comparable between patients with 
erosive and non-erosive hand osteoarthritis and were neither associated with signs of clinical 
nor laboratory markers of inflammation [102]. In addition, resistin has been shown to both 
induce and be induced by several proinflammatory cytokines, such as TNF-α or IL-6 (via the 
NF-κB pathway), in peripheral blood mononuclear cells, indicating that resistin can enhance 
its own activity by a positive feedback mechanism. Interestingly, injection of recombinant 
resistin into healthy mouse joints induces infiltration of the synovial tissue with leukocytes, 
which resembles the pathology of rheumatoid arthritis [36]. In general, the local production of 
resistin at sites of inflammation could be suggested of more importance, because it has been 
found in numerous resident and immune cell types within the hyperplastic rheumatic synovial 
tissue [30, 31, 103-106].  
Patients with systemic rheumatic diseases generally have an increased prevalence of 
atherosclerosis [107]. Very recently, a decline in serum levels of resistin after TNF-α blocking 
therapy has been shown; it is evident that this therapy, in addition to reducing joint 
inflammation, can concomitantly improve the cardiovascular prognosis in inflammatory 
disorders [108, 109]. An association between serum resistin levels, inflammation, bone 
mineral density, and renal functions has been demonstrated in patients with systemic lupus 
erythematosus (SLE) [110]. Increased expression of resistin corresponds to the intensity of 
lymphocytic inflammation in the salivary glands of patients with primary Sjogren´s syndrome 
[111]. Serum resistin is elevated in patients with the skin form of psoriasis but without joint 
involvement, and it correlates with the disease severity as assessed by the Psoriasis Area and 
Severity Index (PASI) [112, 113]. 
 
 16 
Resistin is associated with the laboratory findings and disease activity of several rheumatic 
diseases. However, its role and predictive value in autoimmune inflammatory diseases 
remains to be elucidated.  
 
Resistin and bone metabolism 
Rosen and Bouxsein asked a provocative question: does fat infiltration in the bone marrow 
cause low bone mass, or is it only a result of bone loss [114]? There is growing evidence that 
leptin as well as adiponectin can modulate bone metabolism [115, 116, 117]. 
Resistin expression has been found in murine preosteoblasts, preosteoclasts, and in primary 
human bone marrow stem cells, as well as in mature human osteoblasts [118]. Resistin 
stimulates osteoclast differentiation and NF-κB activity, the major signaling pathway 
involved in osteoclastogenesis. The observed, although weak, decrease in the RANKL/OPG 
mRNA ratio may indicate an indirect inhibitory effect, while an increase in IL-6 secretion 
may result in a stimulatory effect on osteoclastogenesis [118]. In one study, resistin levels 
correlated with a marker of bone metabolism, carboxyterminal cross-linked telopeptide of 
type I collagen (ICTP), while it was inversely related with bone mineral density [101]. These 
data, however, were not observed in Chinese men [119].  
These findings indicate that resistin may play a role in bone remodeling. 
 
Resistin and inflammatory bowel diseases 
Increased serum resistin levels have been detected in both Crohn’s disease and ulcerative 
colitis patients [120, 121, 122]. In addition, resistin correlated with the disease activity score, 
white blood cell count, and CRP in patients with Crohn’s disease [121, 122]. In contrast to 
leptin and adiponectin, resistin significantly decreases after TNF-α blocking therapy in 
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patients with inflammatory bowel diseases and has been proposed as a marker of successful 
therapy, similar to the patients with rheumatoid arthritis [123]. 
From the family of resistin-like molecules, RELM-β, as mentioned above, is predominantly 
expressed by goblet and epithelial cells within the colonic epithelium. It is involved in 
regulating intestinal homeostasis [124, 125]. When secreted extracellularly, it can act as 
a regulatory molecule in luminal molecule recognition and transportation across the epithelial 
barrier and has been shown to bind to nematodes and to possess anti-chemotactic activity 
against the parasites. Moreover, RELM-β-mediated dysregulation of enterocyte innate 
immune mediators and IL-13-dependent expression might act in inflammatory bowel disease 
pathology. Up-regulation of RELM-β in a model of mouse cystic fibrosis intestine suggests 
that it also has a role in the cystic fibrosis-related disorder [126].  
Resistin has been suggested as an independent predictor of disease activity in patients with 
inflammatory bowel disease and has been proposed as a marker of successful therapy [121, 
123]. Moreover, RELM-β has anti-parasitic effects and may play a role in the pathology of 
inflammatory bowel diseases. 
 
 
Resistin and chronic kidney disease 
Resistin has been shown to be associated with both the rate of glomerular filtration and the 
inflammatory status, but not insulin resistance in chronic kidney disease [127]. Increased 
serum resistin has also been measured in pediatric patients with chronic renal failure and end 
stage renal disease, suggesting that renal functions are an important factor in regulating the 
systemic levels of resistin [128]. Resistin was also correlated with TNF-α, suggesting that it 
have a role in the sub-clinical inflammatory state of chronic kidney disease [54]. Resistin may 
also interfere with the chemotactic ability and oxidative burst of polymorphonuclear 
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leukocytes and might contribute to the disturbed immune response in conditions with 
increased serum resistin levels, such as uremia [129].  
Resistin is associated with chronic kidney disease, which is characterized by a subclinical 
inflammatory state. Glomerular filtration may represent a crucial metabolic pathway for the 
elimination of resistin [130].  
 
Resistin and asthma 
Although the prevalence of asthma and obesity is increasing in recent decades, very little is 
known about the possible association between these two disorders. Elevated plasma resistin 
levels in asthmatic patients compared with control individuals as well as resistin levels that 
increase with disease severity have been demonstrated in the asthma cohort [131]. On the 
other hand, atopic asthmatic children have lower resistin levels compared to non-atopic 
asthma and control groups [132].  
The potential of resistin and its relationship to disease activity in patients with asthma is 
unclear and might be the objective of further studies.  
 
Resistin as a potential pharmacological target 
Steppan et al. [3] suggested that resistin may be a hormone with effects on glucose 
metabolism, antagonizing insulin action. Thiazolidindiones (TZDs) are antidiabetic drugs that 
bind as ligands to PPARγ. TZDs decreased circulating resistin levels in both mice and humans 
and inhibited the expression of resistin in cultured 3T3-L1 adipocytes and in white adipose 
tissue in db/db mice [3, 133, 134, 135]. Regarding the effects of resistin on insulin sensitivity, 
the decrease in plasma resistin following TZD therapy may play an important role in 
reversing insulin resistance and its consequences in patients with type 2 diabetes [133]. 
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Moreover, it has been recently shown that higher doses of TZDs reduced bone erosions and 
prevented inflammatory bone loss in an experimental model of autoimmune arthritis [136]. 
As mentioned above, obesity and insulin resistance are associated with higher cardiovascular 
risk factors. Statins (HMG CoA reductases) have been shown to reduce cardiovascular events 
and mortality. Statin treatment resulted in a significant reduction of plasma resistin in patients 
with type 2 diabetes and also downregulated mRNA resistin levels in PBMCs [40, 136]. 
However, niacin, another lipid-lowering drug, decreased resistin plasma levels only 
moderately [137]. Some of the commonly used anti-hypertensive drugs and particularly 
calcium channel blockers (amlodipin) have been shown to decrease plasma resistin levels in 
patients with arterial hypertension; to a lesser extent, an angiotensin-converting enzyme 
inhibitor, ramipril, and angiotensin II type 1 receptor blockade, candesartan, have been shown 
to do the same, but β-blockers, such as atenolol, or thiazide diuretics have not [138].  
While treatment with another angiotensin II type 1 receptor blockade losartan does not modify 
the insulin-induced changes in plasma resistin, it attenuates the response of resistin in adipose 
tissue [139]. Short-term vitamin C supplementation could significantly reduce resistin serum 
levels, independent of changes in inflammatory or metabolic variables in healthy individuals 
[140]. This is interesting with regard to possible participation of resistin in oxidative stress. 
Resistin significantly decreased after the TNF-α blocking therapy in patients with rheumatoid 
arthritis and inflammatory bowel disease [108, 109, 123]. Treatment of patients with the skin 
form of psoriasis with retinoids leads to a normalization of serum resistin levels [113]. This 
could be due to the direct effects of retinoids on resistin expression in 
monocytes/macrophages or adipose tissue, in accordance with the data obtained in mice [113, 
141].  
With respect to the multiple and rather negative involvements of resistin in various human 
pathologies, it is becoming a potential target for their treatment. However, to find any 
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effective therapeutic strategies, the exact role of resistin in their pathophysiology needs to be 
fully established. 
 
Conclusion 
Resistin was first described as a factor contributing to insulin resistance and obesity-related 
diseases, although there is now more (largely circumstantial) evidence that it might be 
involved in inflammatory, endocrine, or tumor diseases. Possible roles for resistin in obesity-
related subclinical inflammation, atherosclerosis and cardiovascular disease, non-alcoholic 
fatty liver disease, rheumatic diseases, malignant tumors, asthma, inflammatory bowel 
disease, and chronic kidney disease have already been demonstrated. Resistin has been 
suggested as an independent predictor of the activity of several diseases. However, research 
on resistin has shown some conflicting results, and conclusive data await new firm evidence 
to elucidate the role of resistin in various disease processes. 
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Table 1. The primary differences between mouse and human resistin 
Feature                                                        Mouse                                                   Human 
Chromosome location                        8 A1; 8 0.37 cM                                            19p13.2 
Genomic organization  
               
Number of amino acids                               114                                                         108 
Secondary structure                       predominantly α-helix                        concentration dependent α-β  shift   
Active form                                          LMW in liver                                              HMW (?) 
                                                        HMW in cardiac muscle 
The main source                             adipocytes                                       immune cells 
 
Abbreviations: LMW, low molecular weight; HMW, high molecular weight; arrowheads and 
arrows denote the positions of the start and stop codons.                    
 
 
 
 
 
 
 
 
 
 
 
73 162 140 78 142 150 763 264 2279 
36 195 128 78 236 376 320 
56,2% 
37,2% 
59,7% 
41,6% 
70,8% 
36,7% 
70,9% 
Mouse 
Human 
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Table 2. Implication of resistin in different pathologies  
 
Abbreviations: TNF, tumor necrosis factor; IL, interleukin; MCP-1, monocyte 
chemoattractant protein; PPARγ, peroxisome proliferator activated receptor γ; DM, diabetes 
Disease/manifestation Functions of resistin Prognostic significance 
Inflammation NFB, MAPK, PI3K activation 
↑ TNFα, IL-6, IL-8, IL-12, MCP-1 
 
Involvement in several inflammatory states
(see below)  
Specific role and prognostic value? 
Insulin resistance 
Diabetes mellitus  
apoptosis of beta cells 
↑ insulin resistance in liver, adipocytes 
and skeletal muscle 
hypothalamus-mediated effect  
inflammatory milieu in adipose tissue 
regulation via PPARγ 
Link between obesity and DM? 
Link to related complications? 
Obesity-associated inflammation 
Potential target for treatment of DM  
Atherosclerosis 
 
↑ proinflammatory cytokines 
↑ VCAM-1, ICAM-1, VEGFR, ET-1,  
↑ MCP-1, MMP, ↓ TRAF3 
↑ foam cell formation  
endothelial dysfunction 
↑ angiogenesis 
smooth muscle cell proliferation 
 
Implicated in the pathogenesis of 
atherosclerosis / cardiovascular diseases 
Marker of coronary atherosclerosis  
Marker of myocardial  ischemic injury   
Potential target for treatment? 
Non-alcoholic fatty 
liver disease  
↑NF-κB, IL-8, MCP-1 in hepatic 
stellate cells  
↑ lipid accumulation? 
Association with stage of NAFLD? 
 
Tumorigenesis ↑ MMP, VEGFR, ↓ TIMP 
↑ angiogenesis  
Implicated in the pathogenesis of cancer? 
Prognostic value? 
Rheumatic diseases 
 
↑  TNFα, IL-6, NF-B activation 
Infiltration of synovial tissue with 
leukocytes, RA-like pannus formation  
Involvement the pathogenesis of rheumatic
diseases  
Specific role and prognostic value? 
Marker of disease activity and successful 
treatment?  
Osteoporosis ↑NF-κB activation, ↑ IL-6   
↓ RANKL/OPG  
Expressed in bone marrow stem cells 
and osteoblast-differentiated cell line 
Osteoclastogenesis 
Bone remodeling 
Marker of bone metabolism?  
Inflammatory bowel 
disease 
↑ proinflammatory cytokines 
RELM-β antiparasitic effect, 
dysregulation of enterocyte immune 
mediators 
↑ serum levels in CD and UC  
Predictor of disease activity? 
Marker of successful therapy? 
Chronic kidney 
disease 
↑ proinflammatory cytokines  
interference with chemotaxis and 
oxidatibe burst of leukocytes? 
↑ inflammatory milieu  
Proinflammatory state of chronic kidney 
disease  
Related to renal functions? 
Marker of disease severity  
Asthma bronchiale ↑ proinflammatory cytokines  Marker of disease severity? 
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mellitus; ET-1, endothelium derived vasoactive factor; VCAM-1, vascular cell adhesion 
molecule; ICAM-1, inter-cellular adhesion molecule 1; MMPs, matrix metalloproteinases; 
VEGFR, vascular endothelial growth factor receptor; TRAF3, TNF receptor – associated 
factor-3; NAFLD, non-alcoholic fatty liver disease; TIMP, tissue inhibitors of 
metalloproteinases; RANKL, receptor activator of NF-κB ligand; OPG, osteoprotegerin; 
PPAR, peroxisome proliferator-activated receptor ; CD, Crohn’s disease; UC, ulcerative 
colitis.  
 
Figure 1. Resistin induced intracellular signaling pathways  
No receptor for resistin has yet been identified. Resistin induces NF-κB activity, resulting in 
the translocation of both the p65 and p50 subunits from the cytoplasm to the nucleus. This 
effect may be through resistin-mediated phosphorylation of the inhibitory protein IκBα and 
the p65 subunit of NF-κB. Resistin activates MAPKs such as Erk or p38 as well as Akt, a 
downstream substrate of PI3K. Resistin increases the cytosolic Ca concentration via both PLC 
activation, leading to the release of Ca from intracellular pools, such as the endoplasmic 
reticulum, and Ca influx from the extracellular environment. Activation of the 
abovementioned signaling pathways via resistin suggests that it has proinflammatory 
potential. 
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Abbreviations: NF-κB, nuclear factor B; IκB, inhibitor of κB; MAPK, mitogen-activated 
protein kinase; ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol 3-
kinase; Ca, calcium; PLC, phospholipase C; IP3, inositol-1,4,5-trisphosphate; IP3R, inositol 
trisphosphate receptor. 
 
Figure 2. Resistin as a potential regulator of inflammation  
 A schematic representation of key pathophysiological signaling pathways that are mediated 
by resistin in immune and resident tissue cells. Resistin has many features of the 
proinflammatory cytokines that activate the transcription factor NF-κB. It is up-regulated 
during monocyte-macrophage differentiation and increases after TNF-α, IL-1β, IL-6, and LPS 
stimulation. Resistin can target several human cells, thereby enhancing inflammatory and 
autoimmune processes. It induces endothelial cell growth and migration, which are involved 
in angiogenesis and tumorigenesis. Together with a glucose-dependent increase in triglyceride 
and cholesterol cellular mass in macrophages, it can contribute to the process of 
atherosclerosis and its related complications. It has been also suggested that resistin can 
endorse osteoclastogenesis via modulation of bone turnover mediators. 
Abbreviations: TNF, tumor necrosis factor; IL, interleukin; MCP-1, monocyte 
chemoattractant protein; ET-1, endothelium derived vasoactive factor; VCAM-1, vascular cell 
adhesion molecule; ICAM-1, inter-cellular adhesion molecule 1, VEGFR, vascular 
endothelial growth factor receptor; TRAF3, TNF receptor – associated factor-3; MMPs, 
matrix metalloproteinases; RANKL, receptor activator of NF-κB ligand; OPG, 
osteoprotegerin; PBMCs, peripheral blood mononuclear cells; LPS, lipopolysaccharide. 
 
 
